{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:05Z","timestamp":1792417385614,"version":"4.4.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Recent advances in single-cell, spatial, and multiomic technologies have provided new insights into the immunopathogenesis and clinical heterogeneity of IgG4-related disease (IgG4-RD). At the same time, several mechanism-based therapies have entered clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Recent studies have identified distinct B-cell, T-cell, myeloid, and stromal populations and their interactions within affected tissues. Type 2 peripheral helper T-cell-associated, granzyme K\n                      <jats:sup>+<\/jats:sup>\n                      cytotoxic T-cell-associated, and age-associated B-cell-related programs may contribute to tissue inflammation and immune dysregulation. Recent studies further suggest that immunopathogenesis varies across clinical phenotypes and may be shaped by additional axes such as allergy and malignancy. Clinical trials have demonstrated efficacy of the CD19-directed B-cell-depleting therapy with inebilizumab and the nondepleting B-cell modulator obexelimab, while Bruton tyrosin kinase inhibition and cellular therapies represent emerging therapeutic approaches.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>IgG4-RD is increasingly recognized as an immunologically heterogeneous fibroinflammatory disease. Integrating immune pathotypes with clinical phenotypes and dynamic biomarkers may enable more individualized treatment and accelerate development of mechanism-based therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001203","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:01:06Z","timestamp":1792414866000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["From immune heterogeneity to targeted therapies in IgG4-related disease"],"prefix":"10.1097","author":[{"given":"Satoshi","family":"Hara","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Mizushima","sequence":"additional","affiliation":[{"name":"General Medicine Co-Creation Center, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1080\/1744666X.2025.2567589","article-title":"Immunopathogenesis of IgG4-related disease in the era of single-cell RNA sequencing and highly multiplex immunofluorescence","volume":"21","author":"Hara","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/25785826.2024.2407224","article-title":"The immunological pathogenesis of IgG4-related disease categorized by clinical characteristics","volume":"48","author":"Akiyama","year":"2025","journal-title":"Immunol Med"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"rkae020","DOI":"10.1093\/rap\/rkae020","article-title":"Current and future advances in practice: IgG4-related disease","volume":"8","author":"Wallace","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41584-025-01240-x","article-title":"IgG4-related disease and other fibro-inflammatory conditions","volume":"21","author":"Peyronel","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1097\/CM9.0000000000003990","article-title":"Pathogenesis exploration of lgG4-related disease: from the traditional central dogma and its remodeling perspective","volume":"139","author":"Guo","year":"2026","journal-title":"Chin Med J"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"968.e14","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3960\/jslrt.24040","article-title":"Activation of fibroblasts by plasma cells via PDGF\/PDGFR signaling in IgG4-related sialadenitis","volume":"64","author":"Kitaoka","year":"2024","journal-title":"J Clin Exp Hematop"},{"key":"R9-20261019","article-title":"Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease","volume":"S0003-4967","author":"Kim","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jaci.2023.11.916","article-title":"Granzyme K- and amphiregulin-expressing cytotoxic T cells and activated extrafollicular B cells are potential drivers of IgG4-related disease","volume":"153","author":"Koga","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20261019","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/ard-2023-224363","article-title":"Single-cell transcriptome analysis profiles cellular and molecular alterations in submandibular gland and blood in IgG4-related disease","volume":"82","author":"Li","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/rheumatology\/keae393","article-title":"Submandibular gland tissue RNAseq and spatial transcriptome analyses in IgG4-related disease","volume":"64","author":"Yamamoto","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13073-025-01567-w","article-title":"Single-cell multiomics analysis revealed the expansion of age-associated B cells in the pancreas of type 1 autoimmune pancreatitis patients","volume":"17","author":"Wang","year":"2025","journal-title":"Genome Med"},{"key":"R14-20261019","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.alit.2026.01.005","article-title":"Extrafollicular Tph2-CD11c+CD21- B cell interactions orchestrate immune dysregulation in IgG4-related disease","volume":"75","author":"Sakamoto","year":"2026","journal-title":"Allergol Int"},{"key":"R15-20261019","first-page":"2409","article-title":"Significant association of CX3CR1+CD8\u200aT cells with aging and distinct clinical features in Sj\u00f6gren's syndrome and IgG4-related disease","volume":"41","author":"Akiyama","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20261019","first-page":"435","article-title":"CCR4+Tfh2 cells specifically produce IL-4 driving the pathological reaction in IgG4-related disease","volume":"43","author":"Akiyama","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"R17-20261019","doi-asserted-by":"crossref","first-page":"keag417","DOI":"10.1093\/rheumatology\/keag417","article-title":"Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease","volume":"65","author":"Shimanuki","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20261019","doi-asserted-by":"crossref","first-page":"1550405","DOI":"10.3389\/fimmu.2025.1550405","article-title":"Polarization of V\u03b42\u200aT cells to a Th2-like phenotype promotes plasmablast differentiation and possesses pro-fibrotic properties in IgG4-related disease","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"R19-20261019","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/14397595.2018.1526357","article-title":"Interleukin 5-producing ST2+ memory Th2 cells in IgG4-related dacryoadenitis and sialadenitis","volume":"29","author":"Yamamoto","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R20-20261019","doi-asserted-by":"crossref","first-page":"1669568","DOI":"10.3389\/fimmu.2026.1669568","article-title":"Autoimmune fibroinflammation in IgG4-related ophthalmic disease: TLR8-dependent signaling pathways and fibrotic remodeling revealed by proteomic profiling","volume":"17","author":"Ma","year":"2026","journal-title":"Front Immunol"},{"key":"R21-20261019","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1093\/rheumatology\/keab096","article-title":"Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease","volume":"60","author":"Rovati","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20261019","doi-asserted-by":"crossref","first-page":"156754","DOI":"10.1016\/j.cyto.2024.156754","article-title":"IL-33\/ST2 enhances MMP-12 expression by macrophages to mediate inflammatory and immune response in IgG4-Related Ophthalmic Disease","volume":"184","author":"Ding","year":"2024","journal-title":"Cytokine"},{"key":"R23-20261019","doi-asserted-by":"crossref","first-page":"42413","DOI":"10.1038\/srep42413","article-title":"Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease","volume":"7","author":"Furukawa","year":"2017","journal-title":"Sci Rep"},{"key":"R24-20261019","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.41052","article-title":"Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via Toll-like receptor 7\/interleukin-33 signaling","volume":"72","author":"Ishiguro","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R25-20261019","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/rheumatology\/keab610","article-title":"Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease","volume":"61","author":"Zhang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20261019","doi-asserted-by":"crossref","first-page":"713779","DOI":"10.3389\/fimmu.2021.713779","article-title":"Plasmacytoid dendritic cells as a new therapeutic target for autoimmune pancreatitis and IgG4-related disease","volume":"12","author":"Minaga","year":"2021","journal-title":"Front Immunol"},{"key":"R27-20261019","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/all.70124","article-title":"The CXCL12-CXCR4 axis mediates lymphocyte immune overactivation in IgG4-related chronic rhinosinusitis","volume":"81","author":"Ding","year":"2026","journal-title":"Allergy"},{"key":"R28-20261019","doi-asserted-by":"crossref","first-page":"750216","DOI":"10.3389\/fphar.2021.750216","article-title":"CXCL12\/SDF-1 in IgG4-related disease","volume":"12","author":"Capecchi","year":"2021","journal-title":"Front Pharmacol"},{"key":"R29-20261019","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2020.01272","article-title":"In vitro IL-6\/IL-6R trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease","volume":"11","author":"Zongfei","year":"2020","journal-title":"Front Immunol"},{"key":"R30-20261019","doi-asserted-by":"crossref","first-page":"1870169","DOI":"10.3389\/fimmu.2026.1870169","article-title":"Spatial transcriptomics reveals an SPP1-centered immune-fibrotic axis associated with fibrosis-related tissue remodeling in IgG4-related disease","volume":"17","author":"Yamamoto","year":"2026","journal-title":"Front Immunol"},{"key":"R31-20261019","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R32-20261019","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.ejim.2025.106459","article-title":"Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multicenter cohort study","volume":"143","author":"Goni","year":"2026","journal-title":"Eur J Intern Med"},{"key":"R33-20261019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10067-025-07781-6","article-title":"Clinical phenotypes and prognosis of IgG4-RD patients with allergy history: a retrospective cohort study","volume":"45","author":"Xue","year":"2026","journal-title":"Clin Rheumatol"},{"key":"R34-20261019","first-page":"1754","article-title":"Distinct impact of malignancy and allergy on the clinical and immunological features of IgG4-related disease","volume":"41","author":"Takanashi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R35-20261019","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-020-02338-1","article-title":"Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study","volume":"22","author":"Zhou","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R36-20261019","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/all.70162","article-title":"Allergen-specific IgE and IgG4 signatures in IgG4-related disease revealed by a large-scale PhIP-seq study","volume":"81","author":"Li","year":"2026","journal-title":"Allergy"},{"key":"R37-20261019","doi-asserted-by":"crossref","first-page":"keag026","DOI":"10.1093\/rheumatology\/keag026","article-title":"Characterization of latent allergen profile and association with clinical features in patients with IgG4-related disease","volume":"65","author":"Wang","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R38-20261019","doi-asserted-by":"crossref","first-page":"e167602","DOI":"10.1172\/jci.insight.167602","article-title":"Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease","volume":"8","author":"Lu","year":"2023","journal-title":"JCI Insight"},{"key":"R39-20261019","doi-asserted-by":"crossref","first-page":"roag057","DOI":"10.1093\/mr\/roag057","article-title":"Exploratory comparison of immune cell compositions across organs in IgG4-related disease","author":"Yamamoto","year":"2026","journal-title":"Mod Rheumatol"},{"key":"R40-20261019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11926-026-01224-0","article-title":"Management of IgG4-related disease","volume":"28","author":"Hern\u00e1ndez-Molina","year":"2026","journal-title":"Curr Rheumatol Rep"},{"key":"R41-20261019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40266-024-01172-3","article-title":"Pharmacological management of IgG4-related disease: from traditional to mechanism-based targeted therapies","volume":"42","author":"Akiyama","year":"2025","journal-title":"Drugs Aging"},{"key":"R42-20261019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2169\/internalmedicine.3154-23","article-title":"IgG4-related disease: Recent topics on immunological aspects of this disorder and their application in new treatment strategies","volume":"64","author":"Kawano","year":"2025","journal-title":"Intern Med"},{"key":"R43-20261019","first-page":"58","article-title":"Evaluating and predicting disease damage accumulation of IgG4-RD over ten years: utility of the IgG4-related Disease Damage Index","volume":"44","author":"Li","year":"2026","journal-title":"Clin Exp Rheumatol"},{"issue":"106832","key":"R44-20261019","doi-asserted-by":"crossref","first-page":"106832","DOI":"10.1016\/j.ejim.2026.106832","article-title":"Rituximab limits glucocorticoid use in IgG4-related disease: real-world evidence from a large European cohort","author":"Vikse","year":"2026","journal-title":"Eur J Intern Med"},{"key":"R45-20261019","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/rheumatology\/keae248","article-title":"B cell depletion after treatment with rituximab predicts relapse of IgG4-related disease","volume":"64","author":"Lanzillotta","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R46-20261019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejim.2023.07.019","article-title":"B-cell depletion with obinutuzumab for the treatment of IgG4-related disease","volume":"116","author":"Lanzillotta","year":"2023","journal-title":"Eur J Intern Med"},{"key":"R47-20261019","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.xkme.2025.101156","article-title":"Recurrent IgG4-related tubulointerstitial nephritis successfully treated with obinutuzumab: a case report and literature review","volume":"8","author":"Zhu","year":"2025","journal-title":"Kidney Med"},{"key":"R48-20261019","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfab250","article-title":"Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab","volume":"15","author":"Ginth\u00f6r","year":"2021","journal-title":"Clin Kidney J"},{"key":"R49-20261019","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41433-023-02758-8","article-title":"Successful remission induction of IgG4-related ophthalmic disease by obinutuzumab therapy: a retrospective study of 8 patients","volume":"38","author":"Sun","year":"2024","journal-title":"Eye (Lond)"},{"key":"R50-20261019","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"R51-20261019","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2601337","article-title":"Obexelimab for the treatment of IgG4-related disease","author":"Della-Torre","year":"2026","journal-title":"N Engl J Med"},{"key":"R52-20261019","article-title":"A phase 2 trial of rilzabrutinib in IgG4-related disease","volume":"S0003-4967","author":"Stone","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R53-20261019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-026-03741-w","article-title":"Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease","volume":"28","author":"Hu","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"R54-20261019","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2025.11.027","article-title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement","volume":"84","author":"Keitel","year":"2026","journal-title":"J Hepatol"},{"key":"R55-20261019","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2019-216368","article-title":"Dupilumab as a novel steroid-sparing treatment for IgG4-related disease","volume":"79","author":"Simpson","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R56-20261019","doi-asserted-by":"crossref","first-page":"e003026","DOI":"10.1136\/rmdopen-2023-003026","article-title":"IgG4-related disease administered dupilumab: case series and review of the literature","volume":"9","author":"Kanda","year":"2023","journal-title":"RMD Open"},{"key":"R57-20261019","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2665-9913(21)00359-3","article-title":"Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study","volume":"4","author":"Matza","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R58-20261019","doi-asserted-by":"crossref","first-page":"20406223211028776","DOI":"10.1177\/20406223211028776","article-title":"Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry","volume":"12","author":"Zongfei","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"R59-20261019","doi-asserted-by":"crossref","first-page":"103296","DOI":"10.1016\/j.autrev.2023.103296","article-title":"Successful treatment of IgG4-related disease with tocilizumab monotherapy","volume":"22","author":"Akiyama","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R60-20261019","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00277-022-04787-x","article-title":"Two cases of refractory IgG4-related disease successfully treated with tocilizumab","volume":"101","author":"Ong","year":"2022","journal-title":"Ann Hematol"},{"key":"R61-20261019","doi-asserted-by":"crossref","first-page":"1734761","DOI":"10.3389\/fimmu.2026.1734761","article-title":"Tocilizumab in the treatment of IgG4-related disease involving the carotid artery-case report and literature review","volume":"17","author":"Ding","year":"2026","journal-title":"Front Immunol"},{"key":"R62-20261019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-026-03743-8","article-title":"Reassessing the role of watchful waiting strategy for IgG4-related disease: a real-world study","volume":"28","author":"Liao","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"R63-20261019","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.70056","article-title":"First-year IgG dynamics in IgG4-related disease: a critical window for predicting long-term outcomes","volume":"78","author":"He","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"R64-20261019","doi-asserted-by":"crossref","first-page":"26601","DOI":"10.1038\/s41598-026-57144-7","article-title":"Proof-of-concept study: longitudinal immune biomarker signatures in treatment-na\u00efve IgG4-related disease","volume":"16","author":"Lopez-Gomez","year":"2026","journal-title":"Sci Rep"},{"key":"R65-20261019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/medicina62020323","article-title":"Immunological biomarkers to assess activity and treatment response in IgG4-related disease","volume":"62","author":"Moya-Alvarado","year":"2026","journal-title":"Medicina (Kaunas)"},{"key":"R66-20261019","doi-asserted-by":"crossref","first-page":"keag034","DOI":"10.1093\/rheumatology\/keag034","article-title":"IgG4 surge and relapse: determining the predictive threshold for IgG4 rising kinetics in IgG4-related disease","volume":"65","author":"Wang","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R67-20261019","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13075-026-03787-w","article-title":"Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease","volume":"28","author":"Hao","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"R68-20261019","article-title":"Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease","volume":"S0003-4967","author":"Bonaso","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R69-20261019","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:01:13Z","timestamp":1792414873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001203","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}